Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) just unveiled an update.
Imricor reported that FY2025 marked a pivotal year as it advanced its MRI-guided cardiac ablation platform with multiple second-generation products securing CE Mark approvals under the EU MDR and key components, including the Vision-MR Diagnostic Catheter and NorthStar, obtaining U.S. FDA clearance early in 2026. The company also launched landmark clinical initiatives such as the first-in-human ischemic VT ablation under real-time MRI guidance, expanded its VISABL trials across additional U.S. sites, and completed human factors studies involving physicians from nearly 20 hospitals.
Commercially, Imricor finished building and training its European sales team, growing its European customer pipeline from seven to 40 sites, while progressing Middle East expansion with two iCMR labs under construction in Saudi Arabia and an accredited summit in Riyadh. Financially, FY2025 revenue was modest at US$292,000 due to customers prioritising clinical trial enrolment, but the company ended the year with approximately US$40.8 million in cash and marketable securities and around US$19 million in operating cash outflows, underpinning its push to scale adoption of its MRI-native technology.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. is a medical technology company focused on enabling interventional cardiac procedures to be performed under real-time MRI guidance instead of traditional x-ray fluoroscopy. The company develops MRI-compatible capital equipment, including its NorthStar 3D mapping system and Advantage-MR EP recorder/stimulator, along with single-use ablation and diagnostic catheters and related tools, targeting cardiac ablation markets in Europe, Saudi Arabia, New Zealand and, pending approvals, the U.S. and other regions.
Average Trading Volume: 208,829
Technical Sentiment Signal: Buy
Current Market Cap: A$705M
For detailed information about IMR stock, go to TipRanks’ Stock Analysis page.